Bioverativ Therapeutics Inc. drugs
3 results
Alprolix (coagulation factor ix (recombinant), fc fusion protein)
(Coagulation Factor IX (Recombinant), Fc Fusion Protein)Bioverativ Therapeutics Inc.
Usage: ALPROLIX is indicated for adults and children with hemophilia B for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce bleeding frequency. It is not intended for immune tolerance induction.
Altuviiio (antihemophilic factor (recombinant), fc-vwf-xten fusion protein-ehtl)
(Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl)Bioverativ Therapeutics Inc.
Usage: ALTUVIIIO is indicated for adults and children with hemophilia A to reduce bleeding episodes through routine prophylaxis, on-demand treatment, and perioperative management. It is not indicated for treating von Willebrand disease.
Eloctate (antihemophilic factor (recombinant), fc fusion protein)
(Antihemophilic Factor (Recombinant), Fc Fusion Protein)Bioverativ Therapeutics Inc.
Usage: ELOCTATE is indicated for adults and children with Hemophilia A for on-demand treatment of bleeding episodes, perioperative management, and routine prophylaxis to reduce bleeding frequency. It is not intended for treating von Willebrand disease.